Regulation of human skin mast cell histamine release by PDE inhibitors

N. Eskandari a,*, R. Bastan b, P.T. Peachell c

a Department of Immunology, Faculty of Medicine, Isfahan University of Medical Sciences, Postal code: 81744-176, Isfahan, Iran
b Department of Immunopharmacology, Faculty of Medicine, Karaj, Iran
c Department of Immunology, Faculty of Medicine, Sheffield University of Medical Sciences, Yorkshire, UK

Received 11 June 2013; accepted 20 July 2013
Available online 11 November 2013

KEYWORDS
Mast cell; Histamine; PDE

Abstract
Background: Mast cell and basophiles are thought to be central to inflammation that has an allergic basis as allergens activate these cells in an IgE-dependent manner to generate mediators such as histamine, eicosanoids and cytokines. Phosphodiesterase (PDE) is known to exist as multiple molecular forms of enzyme that metabolise the second messengers. Studies of our own have shown that, of a variety of isofom-selective drugs, the PDE4-selective inhibitors, such as rolipram, attenuate the IgE-mediated release of histamine from human basophiles but not from human lung mast cells (HLMC).

The main aim of the present study was to characterise the type and role of PDEs regulating human skin mast cells by using selective and non-selective PDE inhibitors.

Methods: Cells were pre-treated for 15 min with these agents and then challenged with an optimal releasing concentration of anti IgE (1:300) for a further 25 min for the release of histamine.

Results: The data show that all the selective PDE-inhibitor compounds (10−5 M) were ineffective whereas the non-selective PDE inhibitor, theophylline (10−3 M), inhibited histamine release from HSMC (74 ± 4% inhibition; p < 0.05). None of the selective PDE inhibitors had any effect on histamine release from HLMC whereas, in basophiles, compounds with activity at PDE 4 (rolipram, denbufylline, Ro-2017, Org 30029) were effective inhibitors of histamine release.

Conclusion: The data suggest that unlike most inflammatory cells, PDE-selective inhibitors are ineffective stabilisers of HSMC activity which is similar to HLMC.

© 2013 SEICAP. Published by Elsevier España, S.L.U. All rights reserved.

Introduction
At least eleven different classes of phosphodiesterase (PDE) have been identified based on structural and functional criteria.1-4 Enzymes within this family are found in most pro-inflammatory and immune cells where they
are important regulators of the metabolism of cyclic nucleotides. Of the eleven PDE isoenzymes, types 3 and 4 hydrolyse CAMP and type 5, cGMP. The activity of PDEs can be modulated by inhibitors. These inhibitors can be divided into distinct categories: (a) classical non-selective inhibitors of PDE activity such as theophylline, and 3-isobutyl-1-methylxanthine (IBMX), and (b) selective PDE inhibitors such as 8-methoxy-methyl-IBMX (8-Me-IBMX; PDE 1 inhibitor), siguazodan (PDE 3 inhibitor), rolipram and denbufylline (PDE 4 inhibitors) and zaprinast (PDE 5 inhibitor). Pharmacological investigations, using selective and non-selective inhibitors of PDE isoenzymes, have shown that PDE type 3 and 4 inhibitors are more effective than PDE type 1, 2 and 5 inhibitors in inflammatory cells (8–9).

Since PDEs hydrolyse CAMP and cGMP, the mechanism by which PDE inhibitors act is to elevate levels of these cyclic nucleotides. Some PDEs hydrolyse CAMP (PDE 4) preferentially whereas others are cGMP-selective (PDE 5). Cyclic AMP and cyclic GMP, as intracellular messengers, play vital roles regulating inflammatory cell activity (9). Since CAMP and cGMP are almost unable to penetrate intact cell membranes, several hundred cyclic nucleotide analogues, with hydrophobic substituent, have been synthesised and have been widely used to elucidate the functional role of CAMP and cGMP signal cascades in biological systems. Four of these, namely, 2′-O-dibutyrylguanosine 3′,5′-cyclic monophosphate (Bu₂-cGMP), 2′-O-dibutyryladenosine 3′,5′-cyclic monophosphate (Bu₂-cAMP), 8-bromo-cyclic 3′,5′-adenosine monophosphate (8-CAMP) and 8-bromo-cyclic 3′,5′-guanosine monophosphate (8-CGMP) have received major attention and are widely used as tools for testing the role of CAMP/cGMP and protein kinase A (PKA)/protein kinase G (PKG) in biological systems because CAMP and cGMP exert their physiological functions almost solely via activation of PKA and PKG, respectively.

The main aim of the present study was to characterise the type and role of PDEs regulating human skin mast cells by using selective and non-selective PDE inhibitors. Secondly, a comparison of the effects of these inhibitors on related cell types, human lung mast cells and basophiles, was also undertaken. Thirdly, an investigation of the effects of non-hydrolysable analogues of CAMP and cGMP on skin mast cells was also undertaken to determine the role of cyclic nucleotides in the regulation of skin mast cells.

Materials and methods

Buffers

Phosphate-buffered saline (PBS) was employed in these studies. PBS contained (mM): NaCl 137; Na₂HPO₄·12H₂O 8; KCl 2.7; KH₂PO₄ 1.5. PBS—bovine serum albumin (BSA) was PBS which additionally contained: CaCl₂·2H₂O 1 mM; MgCl₂·6H₂O 1 mM; glucose 5.6 mM; BSA 1 mg ml⁻¹; DNase 15 μg ml⁻¹. PBS—human serum albumin (HSA) was PBS additionally supplemented with: CaCl₂·2H₂O 1 mM; MgCl₂·6H₂O 1 mM; glucose 5.6 mM; HSA 30 μg ml⁻¹. The pH of all PBS buffers was titrated to 7.3.

Preparation of inhibitors and stimuli

Phosphodiesterase (PDE) inhibitors were made up as follows: rolipram, IBMX, Org 30029, 8-methoxy-methyl-IBMX, denbufylline and Ro-201724 were made up as 10⁻¹ M and 10⁻² M stock solutions in 10% DMSO. Siguazodan and theophylline were made up as 1 mM and 10 mM stock solution, respectively, in PBS. Zaprinast was prepared as a 100 mM stock solution in 0.1 M NaOH. Cyclic nucleotide analogues were made up as follows: 8-bromo-c-AMP, 8-bromo-c-GMP, Bu₂-cAMP and Bu₂-cGMP were prepared as 100 mM stock solutions made in PBS daily. The stimulus used in mediator release experiments was polyclonal goat anti-human IgE which was prepared according to the manufacturer’s instructions. The lyophilised powder was reconstituted in 2 ml of ultra-pure H₂O.

Isolation of basophiles, human lung mast cells and skin mast cells

Mixed leucocyte preparations were obtained from whole blood (from healthy and different volunteers) by dextran sedimentation. Briefly 50 ml of venous blood was mixed with 12.5 ml of 6% dextran and 5 ml of 100 mM EDTA, and then allowed to sediment for 90 min at room temperature. The upper buffy coat layer was removed; cells were recovered by centrifugation (400 × g, 8 min) and washed twice with PBS. These mixed cell preparations were used in the histamine release experiments. Mast cells were isolated from normal human lung tissue by a modification of the method described by Ali and Pearce (1985). Macroscopically normal tissue from lung resections of patients was obtained with the approval of the Local Research Ethics Committee. The tissue was chopped vigorously for 10 min with scissors in a small volume of PBS buffer and then washed over a nylon mesh (100 μm pore size; Incamesh, Warrington, UK) with 0.5–11 of PBS buffer to remove lung macrophages. The tissue was reconstituted in PBS—BSA (10 ml per gram of tissue) containing collagenase Ia (0.1 mg ml⁻¹ of PBS—BSA) and agitated by using a water-driven magnetic stirrer immersed in a water bath set at 37°C. The supernatant was separated from the tissue by filtration over nylon mesh. The collagenase-treated tissue was then reconstituted in a small volume of PBS—BSA buffer and disrupted mechanically with a syringe. The disrupted tissue was then washed over nylon gauze with PBS—BSA. The pooled filtrates were sedimented (400 × g, room temperature, 8 min), the supernatant discarded and the pellets reconstituted in PBS—BSA (100 ml). The pellet was washed twice more. Mast cells were visualised by microscopy using an alcin blue stain. Of the total cells, 3–13% were mast cells. This method generated 2–9 × 10⁶ mast cells per gram of tissue. Mast cells prepared in this manner were used in mediator release experiments.

Methods

Histamine release experiments were performed in PBS buffer and assessed in duplicate. Cell suspensions of about 2 × 10⁴ human mast cells were used per sample. Cells were incubated for either 10 or 15 min with the desired concentration of drug in a total volume of, usually, 300 μl and
then 30 μl anti-human IgE (1/300 or 1/3000 for mast cells or basophiles, respectively) was added. Histamine release was allowed to proceed for 25 (mast cells) or 45 (basophiles) min at 37 °C (Ennis, 1991). Histamine release reactions were terminated by adding 750 μl PBS to all samples. The samples were centrifuged (400 × g, 4 min, RT) and the histamine present in the cell supernatants was measured by a modification of the automated fluorometric technique of. Total histamine content of the cells was determined by lysing aliquots of the cells with 1.8% (v/v) perchloric acid. Cells incubated in buffer alone served as a measure of spontaneous histamine release. Histamine release was calculated as a percentage of the total histamine content after subtracting spontaneous histamine release.

Data analysis

Maximal responses (E_{max}) and potencies (pEC_{50}) were determined by non-linear regression analysis (GraphPad Prism, version 3.0a). To determine whether there was any difference in the responses after treatments with drugs, repeated measures analysis of variance was performed.

Materials

The following were purchased from the sources indicated; anti-human IgE, aprotinin, BSA, collagenase, dimethyl sulfoxide, DNase, Dowex AG-50W, Dowex AG1-X8, dithiothreitol, HSA, leupeptin, Percoll, phenyl methyl sulphonyl fluoride, soybean trypsin inhibitor, Tween 20, Triton X-100 (all Sigma, Poole, UK); EDTA, calcium chloride and magnesium chloride (BDH, Poole, UK); goat polyclonal anti-human IgE, human serum albumin (HSA), dimethyl sulfoxide (DMSO), sodium metabisulphite, rolipram, zaprinast, 3-isobutyl-1-methylxanthine (IBMX), 8-methoxy-methyl-IBMX, theophylline, isoprenaline, N\textsuperscript{6},2\textsuperscript{′}-O-dibutyryladenosine 3′,5′-cyclic monophosphate (Bu\textsubscript{2}-cAMP) and N\textsuperscript{6},2\textsuperscript{′}-O-dibutyrylguanosine 3′,5′-cyclic monophosphate (Bu\textsubscript{2}-cGMP); Org 30029 (gift from Dr CD Nicholson, Organon, UK); denbufylline (Beecham Pharmaceuticals, UK); 8-Bromo-cAMP, 8-Bromo-cGMP, and siguazodan (Tocris Cookson Ltd., UK); ethanol (BDH, Pool, UK); Ro 20-1724 (Research Biochemicals Incorporated, USA).

Results

Effects of PDE inhibitors on IgE-mediated histamine release from skin mast cells

The effects of non-selective PDE inhibitors, theophylline and IBMX, on histamine release from human skin mast cells (HSMC) were investigated. Cells were incubated with increasing concentrations of PDE inhibitors for 15 min before challenge with anti-IgE (1:300). The PDE inhibitors attenuated IgE-mediated histamine release in a dose-dependent manner and to a statistically significant (p < 0.05) extent. IBMX was a more potent inhibitor than theophylline of IgE-mediated histamine release in HSMC. EC\textsubscript{50} values for the IBMX and theophylline inhibition of histamine release from HSMC were 0.1 mM and 1 mM, respectively (Fig. 1).

Effects of cAMP and cGMP analogues on mast cells

The non-selective inhibitors, IBMX and theophylline, are likely to exert effects on HSMC by elevating cAMP and/or cGMP. To investigate the roles of cAMP and cGMP on HSMC the effects of cell-permeant, non-hydrolysable analogues of cAMP and cGMP were studied. The effects of Bu\textsubscript{2}-cAMP, Bu\textsubscript{2}-cGMP, 8-Br-cAMP and 8-Br-cGMP on IgE-mediated histamine release from HSMC were studied. Cells were pre-treated for 15 min in the presence of increasing concentrations (3 × 10\textsuperscript{−3}–3 × 10\textsuperscript{−5} M) of these cyclic nucleotide analogues. Then the cells were challenged with an optimal releasing concentration of anti-IgE (1:300) for a further 25 min. Results are expressed as the percent inhibition of the control release, which was 19 ± 4%. Statistically significant (p < 0.01) levels of inhibition are indicated by asterisks. Values are means ± SEM, n = 5.

Effects of selective PDE inhibitors on HSMC, HLMC, and basophiles

Because PDE 4 is the predominant isoform in inflammatory cells,\textsuperscript{8,9} the effects of the PDE 4-selective inhibitor, rolipram, on IgE-mediated histamine release from HSMC were studied. Cells were pre-treated for 15 min with increasing concentrations of rolipram (10\textsuperscript{−10}–10\textsuperscript{−5} M) or
DMSO (vehicle) then triggered with an optimal releasing concentration of anti-IgE (1:300) for a further 25 min for histamine release. Rolipram (and DMSO over the same equivalent vehicle concentration range of rolipram) failed to inhibit histamine release from HSMC (data not shown).

The inability of rolipram to stabilise HSMC responses prompted us to investigate the effects of a wide range of selective PDE inhibitors on the IgE-mediated histamine release from HSMC. Cells were pre-treated for 15 min with these agents and then challenged with an optimal releasing concentration of anti IgE (1:300) for a further 25 min for the release of histamine. The data show (Table 1) that all the selective PDE inhibitor compounds (10⁻⁵ M) were ineffective whereas the non-selective PDE inhibitor, theophylline (10⁻³ M), inhibited histamine release from HSMC (74 ± 4% inhibition; p < 0.05).

For comparative purposes, the effects of these same compounds on the IgE-mediated release of histamine from both HLMC and basophiles were investigated (Table 1). None

Figure 2  Effect of 8-Br-cAMP (■) and 8-Br-cGMP (▲) on human skin mast cells (HSMC). Cells were incubated for 20 min with either 8-bromo-cAMP or 8-Br-cGMP before challenge with an optimal releasing concentration of anti-IgE (1:300). Histamine release was allowed to proceed for 25 min. Results are presented as the percent inhibition of the control histamine release which was 15 ± 3%. Values are means ± SEM, n = 6.

Figure 3  Effect of Bu₂-cAMP (■) and Bu₂-cGMP (▲) on human skin mast cells (HSMC). Cells were incubated for 20 min with either Bu₂-cAMP or Bu₂-cGMP before challenge with an optimal releasing concentration of anti-IgE (1:300). Histamine release was allowed to proceed for 25 min. Results are presented as the percent inhibition of the control histamine release which was 18 ± 2%. Values are means ± SEM, n = 10.

Figure 4  Effect of 8-Br-cAMP (■) and 8-Br-cGMP (▲) on human lung mast cells (HLMC). Cells were incubated for 20 min with either 8-Br-cAMP or 8-Br-cGMP before challenge with an optimal releasing concentration of anti-IgE (1:300). Histamine release was allowed to proceed for 25 min. Results are presented as the percent inhibition of the control histamine release which was 38 ± 3%. Values are means ± SEM, n = 3.

Figure 5  Effect of Bu₂-cAMP (■) and Bu₂-cGMP (▲) on human lung mast cells (HLMC). Cells were incubated for 20 min with either Bu₂-cAMP or Bu₂-cGMP before challenge with an optimal releasing concentration of anti-IgE (1:300). Histamine release was allowed to proceed for 25 min. Results are presented as the percent inhibition of the control histamine release which was 43 ± 8%. Values are means ± SEM, n = 4.

Table 1  Effects of selective PDE inhibitors on histamine release from human skin mast cells (HSMC), human lung mast cells (HLMC), and human peripheral blood basophils.

<table>
<thead>
<tr>
<th>PDE inhibitor class</th>
<th>HSMC</th>
<th>HLMC</th>
<th>Basophiles</th>
</tr>
</thead>
<tbody>
<tr>
<td>8-Br-cAMP (1)</td>
<td>16.0 ± 4.9</td>
<td>9.4 ± 4.1</td>
<td>6.9 ± 2.7</td>
</tr>
<tr>
<td>Siguazodan (3)</td>
<td>20.3 ± 4.9</td>
<td>9.5 ± 2</td>
<td>5.0 ± 5.5</td>
</tr>
<tr>
<td>Org 30029 (3/4)</td>
<td>0.9 ± 7.2</td>
<td>9.3 ± 3</td>
<td>45.9 ± 1.8*</td>
</tr>
<tr>
<td>Rolipram (4)</td>
<td>23.3 ± 6.2</td>
<td>10.2 ± 4.5</td>
<td>67.5 ± 2.2*</td>
</tr>
<tr>
<td>Denbufylline (4)</td>
<td>20.1 ± 5</td>
<td>11.5 ± 2.7</td>
<td>49.3 ± 1.0*</td>
</tr>
<tr>
<td>Ro-2017 (4)</td>
<td>17.5 ± 6</td>
<td>9.5 ± 5.3</td>
<td>40.9 ± 2.4*</td>
</tr>
<tr>
<td>Zaprinast (5)</td>
<td>13.3 ± 5.5</td>
<td>9.5 ± 3</td>
<td>10.6 ± 8.8</td>
</tr>
<tr>
<td>Theophylline N.S.</td>
<td>74.2 ± 4.2*</td>
<td>71.3 ± 4.1*</td>
<td>77.8 ± 2.1*</td>
</tr>
</tbody>
</table>

N. Eskandari et al.
of the selective PDE inhibitors had any effect on histamine release from HLMC whereas, in basophils, compounds with activity at PDE 4 (rolipram, denbufylline, Ro-2017, Org 30029) were effective inhibitors of histamine release.

Discussion

The results of the present study show that theophylline and IBMX act as effective inhibitors of IgE-mediated histamine release from HSMC. These results suggest that inhibition of PDE can lead to the reduction of the secretory response in skin mast cells. Inhibition of PDE would be expected to cause increases in cyclic nucleotides. Alternative studies indicate that treatment of HLMC with IBMX causes intracellular elevations in cyclic AMP although, the effect that non-selective PDE inhibitors have on cGMP content in human mast cells is not known.

In order to gain a better understanding of the roles of cGMP and cAMP in HSMC, we investigated the effects of cell-permeant and non-hydrolysable analogues of these cyclic nucleotides. Neither 8-Br-cAMP nor 8-Br-cGMP had any effects in HSMC. Indeed, to determine whether this was a finding restricted to HSMC, the effects of these analogues on HLMC were investigated. These analogues were ineffective on these cells and further studies from our group have shown that 8-bromo derivatives are ineffective in basophils. This could be because the 8-bromo derivatives are not very cell-permeant. Therefore, we decided to look at alternative analogues Bu<sub>1</sub>-cAMP and Bu<sub>2</sub>-cGMP. Both analogues were effective inhibitors of histamine release from HSMC, suggesting that both cAMP and cGMP may inhibit the responses of HSMC. However, caution is needed with this interpretation as dibutyryl compounds can be cleaved intracellularly to dibutyrate which is known to affect cell function. However, arguing against an effect of butyrate on HSMC is the finding that Bu<sub>2</sub>-cAMP, and not Bu<sub>2</sub>-cGMP, inhibited histamine release from HLMC.

In further studies the effects of selective PDE inhibitors on HSMC were investigated. None of the inhibitors tested had any effect on the IgE-mediated release of histamine. Interestingly, therefore, HSMC behave much like HLMC which are also insensitive to PDE 4 inhibitors (B). These findings suggest that the PDE that regulates HSMC and HLMC function is something other than PDE 1, 3, 4, or 5. Mast cells, therefore, differ from the vast majority of inflammatory cells which are known to be regulated by PDE 4<sup>1,9</sup>. This includes the human basophile, which the present study has shown to be particularly sensitive to inhibitors of PDE4, confirming previous studies<sup>1,11</sup>. It is possible that the methods used to prepare HSMC or that the maturation state of the isolated mast cells which were obtained from the foreskins of neonates and infants could influence the expression of PDEs. This issue could be resolved by isolating mast cells from adult skin. However, that HLMC are also refractory to PDE4 inhibitors makes it probable that human mast cells, in general, do not express PDE4.

The emphasis of the present study was to characterise PDE isoforms in HSMC. The data suggest that unlike most inflammatory cells, PDE4-selective inhibitors are ineffective stabilisers of HSMC activity. In this regard HSMC are similar to HLMC. However, due to the functional heterogeneity displayed by mast cells the possibility exists that the responses to PDE inhibitors of HSMC and HLMC may not necessarily reflect those of alternative subsets of mast cells. In summary, the present work has shown that although those PDEs appear to regulate HSMC, the nature of this PDE (s) remains uncertain.

Ethical disclosures

Confidentiality of data. The authors declare that no patient data appear in this article.

Right to privacy and informed consent. The authors have obtained the informed consent of the patients and/or subjects mentioned in the article. The author for correspondence is in possession of this document.

Protection of human and animal subjects. The authors declare that the procedures followed were in accordance with the regulations of the responsible Clinical Research Ethics Committee and in accordance with those of the World Medical Association and the Helsinki Declaration.

Conflict of interest

The authors have no conflict of interest to declare.

References

Soluciones en Inmunoterapia y enfermedades alérgicas

beltaoral

Terapia Sublingual en Concentración Única

beltavac®

POLIMERIZADO

Alergoides en pauta rápida

También para NIÑOS

probeltepharma

C/Antonio Belmonte Abellán, 3-7
30100 Murcia, España
T +34 968 858 577
F +34 968 307 498
www.probeltepharma.es
info@probeltepharma.es